ABCAM ORD 0.2P overview

Growing demand for Abcam’s portfolio of in-house products drives calendar 2021 revenues up by 22% at constant exchange rates Acquisition of BioVision completed 26 October 2021 CAMBRIDGE, United Kingdom, March 14, 2022 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; AIM: ABC) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, today announces its final results for the 18-month period ended 31 December 2021 (the ‘period’). The...

CAMBRIDGE, United Kingdom, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; AIM: ABC) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, today announces its interim results for the six- and 12-month periods ended 30 June 2021 (the ‘period’). The Group’s accounting reference date has changed from 30 June to 31 December 1 , therefore these interim financial statements report on both a six- and 12-month period. SUMMARY...

CAMBRIDGE, United Kingdom, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM LSE: ABC; Nasdaq: ABCM) ("Abcam", “the Company” or "the Group"), a global leader in the supply of life science research tools, today announces that it has entered into a definitive agreement to acquire BioVision, Inc. ("BioVision"), a wholly owned subsidiary of Boai NKY Medical Holdings Ltd. (“NKY”), for $340 million (the “Acquisition”). Transaction highlights BioVision is a fast-growing innovator and...

Building on existing three-year collaboration Focusing on co-development of companion and in vitro diagnostic kits to support demand in China CAMBRIDGE, United Kingdom and SHANGHAI, China, April 12, 2021 (GLOBE NEWSWIRE) -- Abcam (AIM: ABC; NASDAQ: ABCM), a global innovator in life science reagents and tools, and MEDx Translational Medicine (MEDx), formerly QIAGEN (Suzhou) Translational Medicine Co., Ltd., a company dedicated to developing companion diagnostics and precision medicine, announced...

CAMBRIDGE, United Kingdom, March 24, 2021 (GLOBE NEWSWIRE) -- Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, announced that Dr Alejandra Solache, SVP of Research & Development received the CiteAb award for ‘ Significant Individual Impact’ and the Company was recognized as ‘ Antibody Supplier Succeeding in Cardiovascular Research’ . On receiving her award, Dr Alejandra Solache, SVP of R&D, Abcam, said: “Thank you very much to the team at...

CAMBRIDGE, United Kingdom, March 08, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; AIM: ABC) (“ Abcam ”, the “ Group ” or the “ Company ”), a global leader in the supply of life science research tools, today announces its interim results for the six month period ended 31 December 2020 (“ H1 2021 ”). SUMMARY PERFORMANCE Reported Adjusted 1 H1 2021 £m H1 2020 £m H1 2021 £m H1 2020 £m Revenue 147.5 138.2 147.5 138.2 Gross profit margin, % 70.9% 69.7% 70.9% 69.7% Operating...

Scaling up R&D, manufacturing and commercial capabilities in Shanghai and Hangzhou Investing in state-of-the-art facilities and equipment to support research, diagnostic and clinical applications CAMBRIDGE, United Kingdom, March 04, 2021 (GLOBE NEWSWIRE) -- Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, announced the expansion of its footprint in China with the opening of new custom-built facilities in Hangzhou and Shanghai. Expanded customer service,...

CAMBRIDGE, United Kingdom, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC; Nasdaq: ABCM) (“ Abcam ” or the “ Company ”), a global leader in the supply of life science research tools, will report its Interim Results for the six-month period ended 31 December 2020 at 12.00 p.m. GMT (7.00 a.m. EST) on Monday, March 8, 2021. Following the announcement, the Company will host a live teleconference and webcast at 2:00 p.m. GMT (9:00 a.m. EST) that same day (details below). To access the...